Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 24, 2024
Product Development
Rare Disease Spotlight: Niemann-Pick pipeline behind two approvals
Therapies aim to enhance lysosomal function to clear cholesterol and glycosphingolipids, mostly via small molecules
BioCentury | Oct 7, 2021
Product Development
Fabry disease’s five-year prospects look up
Comparing the profiles of up-and-coming therapies for Fabry disease
BioCentury | Jun 3, 2021
Deals
June 2 Quick Takes: Genmab, Bolt get bispecific; plus AbbVie, Transine, Sanofi, Puyi
Genmab A/S (NASDAQ:GMAB; CSE:GMAB) and Bolt Biotherapeutics Inc. (NASDAQ:BOLT) partnered to discover and develop bispecific immune-stimulating antibody conjugates using Genmab’s antibodies and
BioCentury | Feb 8, 2020
Finance
Forbion leads Azafaros’ €25M series A, with rare disease vet as chair
Azafaros believes its oral dual inhibitor approach could treat lysosomal storage disorders that affect the brain
BioCentury | Dec 11, 2019
Product Development
The writing has been on the wall for Sanofi’s diabetes, CV business for years
Hudson’s new growth strategy for Sanofi hinges on expanding Dupixent and growing cancer, rare
BioCentury | Sep 11, 2019
Product Development
Pharmas’ challenge: learning from rare disease units while leaving them alone
How Sanofi, Takeda balance keeping rare disease units autonomous while integrating the lessons broadly
BioCentury | Sep 14, 2018
Clinical News
Eagle to meet with FDA to discuss Ryanodex exertional heat stroke data
BioCentury | Mar 9, 2018
Emerging Company Profile
Reviving lixivaptan
How Palladio plans to repurpose lixivaptan for ADPKD
BioCentury | Jul 28, 2017
Regulation
Ganging up in rare disease
What has to happen to implement EMA/FDA proposal for platform trials in rare disease
BioCentury | Jul 21, 2017
Company News
NICE final guidance recommends Sanofi's Cerdelga for Type I Gaucher's
Items per page:
1 - 10 of 96